Boston Scientific’s FilterWire EZ
This article was originally published in The Gray Sheet
Executive Summary
Embolic protection system gains expanded FDA market clearance for use in carotid artery stenting procedures. Previously approved for use in coronary saphenous vein graft interventions in 2004, FilterWire EZ is intended for use with Boston Scientific's NexStent for carotid artery stenting. NexStent gained PMA approval Oct. 27 for carotid artery stenting with the Monorail delivery system (1"The Gray Sheet" Nov. 13, 2006, In Brief). Already approved carotid artery stents with embolic protection systems include Abbott's Acculink stent with Accunet and its Xact stent with Emboshield, as well as Johnson & Johnson/Cordis' Precise stent with AngioGuard. Medtronic expects FDA approval in late 2007 for its Exponent carotid stent with the GuardWire system...
You may also be interested in...
Boston Scientific enters U.S. carotid stent fray
Firm gains FDA approval for its NexStent carotid stent and Monorail delivery system Nov. 3. The self-expanding, self-tapering nitinol stent, manufactured by EndoTex and distributed exclusively by Boston Scientific outside the U.S. since 2005, is indicated for use in patients with carotid artery disease at serious risk of surgery. The firm had previously anticipated approval in the second quarter of 2007. A second carotid stent from Boston Scientific, the Carotid WallStent Monorail, remains stalled in review due to hang-ups from a corporate warning letter the firm received last January (1"The Gray Sheet" Sept. 11, 2006, p. 6)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.